Healthy Extracts (HYEX)
OTHER OTC:HYEX
Top Page
Healthy Extracts
(OTC:HYEX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▲(1.52% Upside)
Action:ReiteratedDate:01/17/26
The score is held down primarily by weak financial performance: despite a sharp revenue rebound and improved gross margin, HYEX remains unprofitable and has returned to TTM cash burn, with leverage/solvency assessment constrained by incomplete TTM balance-sheet fields. Technicals are mildly supportive with price above key moving averages and a positive MACD, but valuation is difficult to justify with a negative P/E and no dividend yield.
Positive Factors
Revenue Growth
The company has demonstrated a significant improvement in revenue, indicating strong market demand and effective sales strategies, which are crucial for long-term growth and market expansion.
Negative Factors
High Leverage
High financial leverage increases risk, potentially limiting the company's ability to invest in growth and manage economic downturns, impacting long-term financial stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company has demonstrated a significant improvement in revenue, indicating strong market demand and effective sales strategies, which are crucial for long-term growth and market expansion.
Read all positive factors
Healthy Extracts (HYEX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.46M
Dividend YieldN/A
Average Volume (3M)1.29K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue Growth19.20%
EPS Growth-19.98%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,870,869
10 Day Avg. Volume902
30 Day Avg. Volume1,290
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)18.22
Price to Sales (P/S)2.40
P/FCF Ratio26.51
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit3.77
Enterprise Value/Ebitda-8.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)$14.12M
Healthy Extracts Business Overview & Revenue Model
Company Description
Healthy Extracts Inc., through its subsidiaries, researches, develops, and markets natural plant-based products in the United States and internationally. It offers heart health nutritional supplements; and neuro products under the KETONOMICS name ...
How the Company Makes Money
Healthy Extracts makes money primarily through the sale of its nutraceutical products. The company generates revenue by selling directly to consumers through its e-commerce platform and by distributing its products through various retail and onlin...
Healthy Extracts Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.59M | 3.11M | 2.49M | 2.25M | 1.47M | 1.28M |
| Gross Profit | 1.88M | 1.91M | 1.62M | 1.37M | 695.08K | -578.44K |
| EBITDA | -799.72K | -183.15K | -2.24M | -910.71K | -1.88M | -2.49M |
| Net Income | -1.17M | -840.67K | -2.47M | -989.96K | -2.04M | -2.65M |
Balance Sheet | ||||||
| Total Assets | 26.19M | 2.38M | 2.64M | 2.78M | 3.03M | 3.12M |
| Cash, Cash Equivalents and Short-Term Investments | 189.45K | 112.02K | 19.44K | 65.65K | 222.10K | 59.20K |
| Total Debt | 1.23M | 941.90K | 1.13M | 593.52K | 342.62K | 177.62K |
| Total Liabilities | 2.13M | 1.97M | 1.68M | 902.79K | 558.84K | 261.61K |
| Stockholders Equity | 24.06M | 410.38K | 954.59K | 1.88M | 2.47M | 2.85M |
Cash Flow | ||||||
| Free Cash Flow | -180.06K | 281.97K | -415.75K | -342.95K | -997.30K | -3.49M |
| Operating Cash Flow | -160.76K | 281.97K | -415.75K | -334.96K | -901.30K | -3.48M |
| Investing Cash Flow | -19.30K | 0.00 | 0.00 | -7.99K | -96.00K | -425.88K |
| Financing Cash Flow | 269.11K | -189.39K | 369.54K | 239.52K | 1.16M | 3.83M |
Healthy Extracts Technical Analysis
Positive
1.97
Price Trends
2.10
Positive
2.02
Positive
2.06
Positive
Market Momentum
-0.02
Negative
67.63
Neutral
88.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYEX, the sentiment is Positive. The current price of 1.97 is below the 20-day moving average (MA) of 2.05, below the 50-day MA of 2.10, and below the 200-day MA of 2.06, indicating a bullish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 67.63 is Neutral, neither overbought nor oversold. The STOCH value of 88.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYEX.
Healthy Extracts Risk Analysis
Healthy Extracts disclosed 11 risk factors in its most recent earnings report. Healthy Extracts reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
An active trading market for our Common Stock may not develop and you may not be able to resell your shares at or above the public offering price. Q4, 2023
2.
We have broad discretion in the use of our cash, and may not use it effectively. Q4, 2023
Healthy Extracts Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $44.49M | -3.67 | -19.05% | ― | -65.77% | 38.61% | |
54 Neutral | $37.01M | -5.64 | -15.64% | ― | -23.60% | -179.33% | |
53 Neutral | $46.96M | -20.99 | -10.54% | ― | 12.21% | 69.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $42.46M | -3.28 | -18.78% | ― | 19.20% | -19.98% | |
45 Neutral | $28.55M | -0.62 | -107.16% | ― | -15.61% | -68.96% | |
40 Underperform | $11.23M | -1.59 | -63.82% | ― | ― | ― |
* Healthcare Sector Average
HYEX
Healthy Extracts
2.52
-0.23
-8.47%
RMTI
Rockwell Med
0.94
-0.17
-15.41%
SCYX
SCYNEXIS
1.00
0.14
15.68%
AYTU
Aytu BioScience
2.66
1.60
150.94%
CPIX
Cumberland Pharmaceuticals
3.14
-1.01
-24.34%
COSM
Cosmos Holdings
0.30
-0.05
-13.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.